Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics

Journal of Medical Toxicology

Volumn 8, Issue 4, 2012, Pages 400-407

  Schaeffer, Tammi ^a,b  

^a ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse deterrent formulation; Opioid abuse; Opioid misuse

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; LISDEXAMFETAMINE; MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYMORPHONE;

ARTHRALGIA; BIOEQUIVALENCE; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MISUSE; GEL; HUMAN; MAXIMUM PLASMA CONCENTRATION; OPIATE ADDICTION; OSTEOARTHRITIS; PLASMA CONCENTRATION-TIME CURVE; PRESCRIPTION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

EID: 84870695489     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-012-0270-y     Document Type: Review

References (64)

1. Manchikanti L, Helm Ii S, Fellows B, Janata JW, Pampati V, Grider JS et al (2012) Opioid epidemic in the United States. Pain Physician 15: ES9-ES38.
2. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D et al (2008) Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300: 2613-20.
3. Manchikanti L, Singh A (2008) Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 11: S63-88.
4. Belouin SJ, Reuter N, Borders-Hemphill V, Mehta H. Prescribing trends for opioids, benzodiazepines, amphetamines, and barbiturates from 1998-2007. Available at http://nac. samhsa. gov/DTAB/Presentations/Aug08/SeanBelouinDTAB0808. ppt. Accessed on 08/14/12.
5. Denisco RA, Chandler RK, Compton WM (2008) Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp Clin Psychopharmacol 16: 417-28.
6. Cicero TJ, Inciardi JA, Munoz A (2005) Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 6: 662-72.
7. Compton WM, Volkow ND (2006) Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 81: 103-7.
8. Substance Abuse and Mental Health Services Administration, NSDUH Series H-41 (2011) Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings.
9. Anonymous (2011) Epidemic: responding to America's prescription drug abuse crisis. Available at http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdf. Accessed on 08/15/12.
10. Farre M, Cami J (1991) Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 86: 1601-6.
11. Webster LR, Bath B, Medve RA (2009) Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs 18: 255-63.
12. Katz N (2008) Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 10: 11-8.
13. U.S.Food Drug and Administration, Center for Drug Evaluation and Research (2012) Code of Federal Regulations Title 21, 21CFR320. 25.
14. U. S. Food Drug and Administration, Center for Drug Evaluation and Research (2012) Code of Federal Regulations Title 21, 21CFR211.
15. Passik SD, Hays L, Eisner N, Kirsh KL (2006) Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 20: 5-13.
16. Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F (2011) Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 37: 205-17.
17. Baum C, Hsu JP, Nelson RC (1987) The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 102: 426-9.
18. Lahmeyer HW, Craig RJ (1987) Pentazocine-naloxone: another "addiction-proof" drug of abuse. Int J Addict 22: 1163-6.
19. Mastropietro DJ, Omidian H (2012) Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm.
20. Anonymous (2012) Oxycontin (oxycodone extended-release) [Product Information]. Available at http://www. accessdata. fda. gov/drugsatfda_docs/label/2012/022272s011lbl. pdf. Accessed on 08/17/12.
21. Hays L, Kirsh KL, Passik SD (2003) Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw 1: 423-8.
22. Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG (2007) Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 164: 1750-6.
23. (R), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee.
24. (R) (OXY) tablets In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials. gov/ct2/show/NCT01101178. NLM Identifier: NCT 01101178.
25. Purdue. To determine the fasting bioequivalence of reformulated OXY tablets and original OxyContin® (OXY) tablets In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials. gov/ct2/show/NCT01101165. NLM Identifier: NCT 01101165.
26. Anonymous (2012) Opana ER (oxymorphone extended-release) [Product information].
27. Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD (2012) Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend.
28. Benedek IH, Jobes J, Xiang Q, Fiske WD (2011) Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther 5: 455-63.
29. Fiske WD, Jobes J, Xiang Q, Chang SC, Benedek IH (2012) The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets. J Pain 13: 90-9.
30. Lin X, Yang S, Gou J, Zhao M, Zhang Y, Qi N et al (2012) A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro/in vivo. J Mater Sci Mater Med 23: 443-55.
31. Webster LR (2007) PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 16: 359-66.
32. Zamloot M, Chao W, Kang LL, Ross J, Fu R (2010) Remoxy: a novel formulation of extended-relase oxycodone developed with ORADUR technology. J Appl Res 10: 88-96.
33. Friedmann N, Klutzaritz V, Webster L (2011) Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 7: 193-202.
34. Friedmann N, Klutzaritz V, Webster L (2011) Long-term safety of Remoxy(R) (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med 12: 755-60.
35. Setnik B, Roland CL, Cleveland JM, Webster L (2011) The abuse potential of Remoxy((R)), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med 12: 618-31.
36. (R) Division Director's review and summary basis for approval.
37. (R) (oxycodone hydrochloride) [package insert]. Available at http://www.accessdata. fda.gov/drugsatfda_docs/label/2011/202080s000lbl.pdf. Accessed on 08/14/12.
38. Leibowitz MT, Zamora CA, Brzeczko AW, Stark JG (2012) A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with Aversion Technology (IRO-A, Oxecta), IRO-A with niacin, and oxycodone hydrochloride (Roxicodone) in healthy adults under fasting conditions. Am J Ther.
39. Anonymous (2010) Acurox (oxycodone hcl and niacin) NDA 22-451.
40. Anonymous (2012) Embeda (morphine sulfate/naltrexone) [product information]. Available at http://www. accessdata. fda. gov/drugsatfda_docs/label/2012/022321s007lbl. pdf. Accessed on 08/15/12.
41. Katz N, Sun S, Johnson F, Stauffer J (2010) ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain 11: 303-11.
42. Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E (2009) Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 29: 777-90.
43. Ruan X (2011) Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond. Expert Opin Pharmacother 12: 999-1001.
44. Anonymous (2012) EMBEDA Website. Available at http://embeda. com/. Accessed on 08/15/12.
45. Anonymous (2011) Suboxone (buprenorphone/naloxone)[product information]. Available at http://www. accessdata. fda. gov/drugsatfda_docs/label/2011/020733s007s008lbl. pdf. Accessed on 08/16/12.
46. Fudala PJ, Johnson RE (2006) Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 83(Suppl 1): S40-7.
47. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K et al (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349: 949-58.
48. Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 154: 230-42.
49. Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN (1998) Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 50: 1-8.
50. Preston KL, Bigelow GE, Liebson IA (1988) Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) 94: 484-90.
51. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL (2009) Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 35: 68-72.
52. Alho H, Sinclair D, Vuori E, Holopainen A (2007) Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88: 75-8.
53. Simojoki K, Vorma H, Alho H (2008) A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy 3: 16.
54. Wu KM, Farrelly JG (2007) Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology. Toxicology 236: 1-6.
55. Jasinski DR, Krishnan S (2009) Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 23: 410-8.
56. Anonymous extended-release (ER) and long-acting (LA) opioid analgesics Risk Evaluation and mitigation Strategy (REMS). Available at http://www. fda. gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290. pdf. Accessed on 07/30/12.
57. U. S. Food Drug and Administration, Center for Drug Evaluation and Research (2010) Guidance for industry: assessment of abuse potential drugs.
58. Anonymous (2007) Title 21 United States Code Controlled Substances Act. Available at http://www. deadiversion. usdoj. gov/21cfr/21usc/812. htm. Accessed on 08/04/12.
59. Turk DC, O'Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, et al. (2012) Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain.
60. Cicero TJ, Ellis MS, Surratt HL (2012) Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 367: 187-9.
61. Karst KR (2012) STOPP act would establish new requirements for tamper-resistant drugs. Available at http://www. fdalawblog. net/fda_law_blog_hyman_phelps/2012/07/stopp-act-would-establish-new-requirements-for-tamper-resistant-drugs. html. Accessed on 08/28/12.
62. Anonymous (2012) Defeating the new Opana for snorting. Available at http://www. topix. com/forum/drug/oxycontin/T7TFK45DARQ6L7QRS. Accessed on 08/28/12
63. Anonymous (2012) Defeating the new "OP" oxycontin. Available at http://www. topix. com/forum/drug/oxycontin/TO8T6EEQ3IBMK99GK/p143. Accessed on 08/28/12.
64. Anonymous (2012) "OXECTA" will soon be replacing all OXYCODONE I. R. Available at http://www. topix. com/forum/drug/oxycontin/TO8T6EEQ3IBMK99GK/p143. Accessed on 08/28/12.